Q98409375

Summary

Q98409375 is a report^[1].

Key Facts

• Q98409375's instance of is recorded as report^[2].
• Q98409375's part of the series is recorded as reports of the 2013/14 legislative session of the Riksdag^[3].
• Q98409375's language of work or name is recorded as Swedish^[4].
• Q98409375's publication date is recorded as +2014-05-13T00:00:00Z^[5].
• Q98409375's significant event is recorded as debate^[6].
• Q98409375's main subject is recorded as medication^[7].
• Q98409375's work available at URL is recorded as http://data.riksdagen.se/dokument/H101SoU22^[8].
• Q98409375's work available at URL is recorded as http://data.riksdagen.se/dokumentstatus/H101SoU22^[9].
• Q98409375's work available at URL is recorded as http://data.riksdagen.se/fil/2CD8C804-656E-4948-AC07-C296914464DF^[10].
• Q98409375's applies to jurisdiction is recorded as Sweden^[11].
• Q98409375's legal citation of this text is recorded as bet. 2013/14:SoU22^[12].
• Q98409375's title is recorded as Ökad tillgänglighet och mer ändamålsenlig prissättning av läkemedel^[13].
• Q98409375's has immediate cause is recorded as Q98122387^[14].
• Q98409375's has immediate cause is recorded as Q97780771^[15].
• Q98409375's has immediate cause is recorded as Q97778716^[16].
• Q98409375's has immediate cause is recorded as Q97778847^[17].
• Q98409375's has immediate cause is recorded as Q97779209^[18].
• Q98409375's has immediate cause is recorded as Q97779519^[19].
• Q98409375's has immediate cause is recorded as Q97780264^[20].
• Q98409375's has immediate cause is recorded as Q97780316^[21].
• Q98409375's has immediate cause is recorded as Q97780866^[22].
• Q98409375's has immediate cause is recorded as Q97781290^[23].
• Q98409375's has immediate cause is recorded as Q97781323^[24].
• Q98409375's has immediate cause is recorded as Q97781460^[25].
• Q98409375's has immediate cause is recorded as Q97781471^[26].